hat
Sa a te yon sanzatann, doub mare etap analiz ki enkli yon plasebo. Objektif la te fòme ke lè l sèvi avèk LGD-4033 te inofansif ak fasil nan vant ak yon dòz pa plis pase 22 mg yon jou.
eng
This was an unplanned, double bind analysis stage that included a placebo. The objective was to form that using LGD-4033 was harmless and easy to stomach with a dose not beyond 22 mg a day.